It also raised the ratio of IFN-γ+ CD4+ T cells (Th1), slightly decreased the level of IL-4+ CD4+ T cells (Th2), and did not change the levels of IL-17A+ CD4+ T cells and FOXP3+ CD4+ T cells in treated tumor-bearing mice. This evidence concerns the gene CD4 and neoplasm.